Get the Stockscreener App
57.94
0.54%
0.31
After Hours:
58.19
0.25
+0.43%
Halozyme Therapeutics Inc stock is traded at $57.94, with a volume of 1.05M.
It is up +0.54% in the last 24 hours and up +14.71% over the past month.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
See More
Previous Close:
$57.63
Open:
$57.91
24h Volume:
1.05M
Relative Volume:
0.65
Market Cap:
$7.37B
Revenue:
$947.36M
Net Income/Loss:
$392.47M
P/E Ratio:
19.19
EPS:
3.02
Net Cash Flow:
$392.71M
1W Performance:
+2.69%
1M Performance:
+14.71%
6M Performance:
+11.55%
1Y Performance:
+65.45%
1-Day Range:
$57.45
$58.20
1-Week Range:
$54.96
$58.20
52-Week Range:
$34.36
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Name
Halozyme Therapeutics Inc
Sector
Industry
Phone
(858) 794-8889
Address
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
57.94 | 7.37B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-19-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-07-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-29-24 | Initiated | TD Cowen | Outperform |
| Jul-24-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-24-23 | Initiated | H.C. Wainwright | Buy |
| May-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Berenberg | Buy |
| Mar-16-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Dec-21-22 | Resumed | Morgan Stanley | Overweight |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Initiated | Evercore ISI | Outperform |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-11-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-21-21 | Reiterated | The Benchmark Company | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jul-01-20 | Initiated | The Benchmark Company | Buy |
| Feb-05-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Buy |
| Nov-05-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-19-18 | Resumed | Piper Jaffray | Neutral |
| May-11-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Oct-16-17 | Reiterated | Piper Jaffray | Overweight |
| Jan-06-17 | Downgrade | Citigroup | Buy → Neutral |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Nov-18-15 | Initiated | Citigroup | Buy |
| Sep-22-15 | Initiated | Barclays | Overweight |
| Jun-22-15 | Reiterated | JP Morgan | Overweight |
| Mar-03-15 | Reiterated | UBS | Buy |
| Feb-18-15 | Reiterated | MLV & Co | Buy |
| Jan-08-15 | Reiterated | MLV & Co | Buy |
View All
Halozyme Therapeutics Inc Stock (HALO) Latest News
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update - MarketBeat
Tempus Wealth Planning LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Insider Sell: Jeffrey Henderson Sells 5,000 Shares of Halozyme T - GuruFocus.com
Hodges Capital Management Inc. Raises Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Earnings Alert: Key Q4 and FY2024 Results Coming February 18Details Inside - StockTitan
Verity Asset Management Inc. Raises Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results - Longview News-Journal
HC Wainwright Reiterates Buy Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat
Demystifying Halozyme Therapeutics: Insights From 8 Analyst Reviews - Benzinga
Koa Wealth Management LLC Boosts Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Swedbank AB Sells 35,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Foster & Motley Inc. Purchases 12,630 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
J&J gets positive EU opinion for subcutaneous Rybrevant (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics Says Non-Small Cell Lung Cancer Treatment Gets Positive Opinion in Europe - Marketscreener.com
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Victoria Advocate
Hantz Financial Services Inc. Decreases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Mount Yale Investment Advisors LLC Sells 9,305 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
High Growth Tech Stocks To Watch In January 2025 - Yahoo Finance
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Might Not Be As Mispriced As It Looks - Simply Wall St
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - MSN
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
7,652 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Acquired by SWP Financial LLC - MarketBeat
Janney Montgomery Scott LLC Boosts Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Marshall Financial Group LLC Invests $1.53 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
(HALO) Investment Report - Stock Traders Daily
HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up - MSN
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Diversify Wealth Management LLC - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by AMI Asset Management Corp - MarketBeat
Sugar Maple Asset Management LLC Buys New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Growth in Short Interest - MarketBeat
Empirical Asset Management LLC Invests $1.09 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Bernzott Capital Advisors Purchases New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Outlook Wealth Advisors LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Converting IV-drip Medications into Shots -January 16, 2025 at 12:29 pm EST - Marketscreener.com
(HALO) Technical Data - Stock Traders Daily
Research Analysts Offer Predictions for HALO FY2025 Earnings - MarketBeat
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
Wells Fargo & Company Has Lowered Expectations for Halozyme Therapeutics (NASDAQ:HALO) Stock Price - Defense World
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Zacks Investment Research
Q1 Earnings Forecast for HALO Issued By Leerink Partnrs - MarketBeat
Analyst Expectations For Halozyme Therapeutics's Future - Benzinga
Halozyme Therapeutics (NASDAQ:HALO) Price Target Cut to $57.00 by Analysts at Wells Fargo & Company - MarketBeat
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $61.44 - MarketBeat
Piper Sandler Increases Halozyme Therapeutics (NASDAQ:HALO) Price Target to $53.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Halozyme Therapeutics (NASDAQ:HALO) Stock - Defense World
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why - MSN
Halozyme raises 2025 guidance, announces $250M stock buyback - MSN
Halozyme Therapeutics Inc Stock (HALO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):